Antiretrovirus specificity and intracellular metabolism of 2',3'- didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324

Molecular Pharmacology

Volumn 50, Issue 5, 1996, Pages 1207-1213

  Balzarini, J ^a   Egberink, H ^b   Hartmann, K ^c   Cahard, D ^e   Vahlenkamp, T ^b   Thormar, H ^d   De Clercq, E ^a   Mcguigan, C ^e  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Department of Infectious Diseases and Immunology   (Netherlands)

^c I Medizinische Tierklinik   (Germany)

^d UNIVERSITY OF ICELAND   (Iceland)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 2',3' DIDEHYDROTHYMIDINE 5' MONOPHOSPHATE; PRODRUG; SO 324; STAVUDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL METABOLISM; DRUG METABOLISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLONEY MURINE SARCOMA ONCOVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VISNA VIRUS;

3T3 CELLS; ALANINE; ANIMALS; ANTIVIRAL AGENTS; CATS; HELA CELLS; HUMANS; INTRACELLULAR FLUID; MICE; MICE, INBRED C3H; MICROBIAL SENSITIVITY TESTS; PRODRUGS; RETROVIRIDAE; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY; STAVUDINE; T-LYMPHOCYTES; THYMIDINE MONOPHOSPHATE;

EID: 0029852052     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hao, Z., D. A. Cooney, N. R. Hartman, C. F. Perno, A. Fridland, A. L. De Vico, M. G. Sarngadharan, S. Broder, and D. G. Johns. Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol. Pharmacol. 34:431-435 (1988).
2. Balzarini, J., P. Herdewijn, and E. De Clercq. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264:6127-6133 (1989).
3. Balzarini, J., D. A. Cooney, M. Dalal, G.-J. Kang, J. E. Cupp, E. De Clercq, S. Broder, and D. G. Johns. 2′,3′-Dideoxycytidine: regulation of its metabolism and antiretroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol. Pharmacol. 32:798-806 (1987).
4. Starnes, M. C., and Y.-C. Cheng. Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem. 262:988-991 (1987).
5. Johnson, M. A., G. Ahluwalia, M. C. Connelly, D. A. Cooney, S. Broder, D. G. Johns, and A. Fridland. Metabolic pathways for the activation of the antiretroviral agent 2′,3′-dideoxyadenosine in human lymphoid cells. J. Biol. Chem. 263:15354-15357 (1988).
6. Johnson, M. A., and A. Fridland. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol Pharmacol. 36:291-295 (1989).
7. Sastry, J. K., P. N. Nehete, S. Khan, B. J. Nowak, W. Plunkett, R. B. Arlinghaus, and D. Farquhar. Membrane-permeable dideoxyuridine 5′-monophosphate analogue inhibits human immunodeficiency virus infection. Mol. Pharmacol. 41:441-445 (1992).
8. Pompon, A., I. Lefebvre, J.-L. Imbach, S. Kahn, and D. Farquhar. Decomposition pathways of the mono- and bis(pivaloyloxymethyl)esters of azidothymidine 5′-monophosphate in cell extract and in tissue culture medium: an application of the "on-line ISRP-cleaning" HPLC technique. Antiviral Chem. Chemother. 5:91-98 (1994).
9. Périgaud, C., G. Gosselin, I. Lefebvre, J.-L. Girardet, S. Benzaria, I. Barber, and J.-L. Imbach. Rational design for cytosolic delivery of nucleoside monophosphates: "SATE" and "DTE" as enzyme-labile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 3:2521-2526 (1993).
10. Périgaud, C., A.-M. Aubertin, S. Benzaria, H. Pelicano, J.-L. Girardet, G. Maury, G. Gosselin, A. Kirn, and J.-L. Imbach. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine. Biochem. Pharmacol. 48:11-14 (1994).
11. McGuigan, C., R. N. Pathirana, N. Mahmood, K. G. Devine, and A. J. Hay. Aryl phosphate derivatives of AZT retain activity against HIV-1 in cell lines which are resistant to the action of AZT. Antiviral Res. 17:311-321 (1992).
12. McGuigan, C., M. Davies, R. N. Pathirana, N. Mahmood, and A. J. Hay. Synthesis and anti-HIV activity of some novel diaryl phosphate derivatives of AZT. Antiviral Res. 24:69-77 (1994).
13. McGuigan, C., R. N, Pathirana, J. Balzarini, and E. De Clercq. Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. J. Med. Chem. 36:1048-1052 (1993).
14. McGuigan, C., D. Cahard, A. Salgado, E. De Clercq, and J. Balzarini. Phosphoramidates as potent pro-drugs of anti-HIV nucleotides: studies in the amino region. Antiviral Chem. Chemother. 7: 31-36 (1996).
15. McGuigan, C., D. Cahard, H. M. Sheeka, E. De Clercq, and J. Balzarini. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by an entirely new mechanism of reverse transcriptase inhibition. J. Med. Chem. 39: 1748-1753 (1996).
16. Balzarini, J., L. Naesens, J. Slachmuylders, H. Niphuis, I. Rosenberg, A. Holy, H. Schellekens, and E. De Clercq. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS 5:21-28 (1991).
17. Hartmann, K, J. Balzarini, J. Higgins, E. De Clercq, and N. C. Pedersen. In vitro activity of acyclic nucleoside phosphonate derivatives against feline immunodeficiency virus in Crandell feline kidney cells and feline peripheral blood lymphocytes. Antiviral Chem. Chemother. 5:13-19 (1994).
18. Thormar, H., J. Balzarini, A. Holy, J. Jindrich, I. Rosenberg, Z. Debyser, J. Desmyter, and E. De Clercq. Inhibition of Visna virus replication by 2′,3′-dideoxynucleosides and acyclic nucleoside phosphonate analogs. Antimicrob. Agents Chemother. 37:2540-2544 (1993).
19. De Clercq, E., and T. C. Merigan. Moloney sarcoma virus-induced tumors in mice: inhibition or stimulation by (poly rI):(poly rC). Proc. Soc. Exp. Biol. Med. 137:590-594 (1971).
20. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (Washington D. C.) 224: 497-500 (1984).
21. Barré-Sinoussi, F., J.-C. Chermann, R. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C., Dauguet, C. Axler-Blin, F. Brun-Vézinet, C. Rouzioux, W. Rozenbaum, and L. Montagnier. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (Washington D. C.) 220:868-871 (1983).
22. Daniel, M. D., N. L. Letvin, N. W. King, M. Kannagi, P. K. Sehgal, R. D. Hunt, P. J. Kanki, M. Essex, and R. C. Desrosiers. Isolation of a T-cell tropic HTLV-III-like retrovirus from macaques. Science (Washington D. C.) 228:1201-1204 (1985).
23. Vahlenkamp, T. W., A. De Ronde, J. Balzarini, L. Naesens, E. De Clercq, M. J. T. van Eijk, M. C. Horzinek, and H. F. Egberink. (R)-9-(2-Phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrob. Agents Chemother. 39: 746-749 (1995).